WO1998038854A1 - Pharmaceutical composition and methods for using it - Google Patents

Pharmaceutical composition and methods for using it Download PDF

Info

Publication number
WO1998038854A1
WO1998038854A1 PCT/US1998/003922 US9803922W WO9838854A1 WO 1998038854 A1 WO1998038854 A1 WO 1998038854A1 US 9803922 W US9803922 W US 9803922W WO 9838854 A1 WO9838854 A1 WO 9838854A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
antihistamine
human
composition
skin
Prior art date
Application number
PCT/US1998/003922
Other languages
French (fr)
Other versions
WO1998038854B1 (en
Inventor
James S. Bass
Original Assignee
Bass James S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/812,410 external-priority patent/US5753247A/en
Application filed by Bass James S filed Critical Bass James S
Priority to JP53861698A priority Critical patent/JP2001514625A/en
Priority to EP98908784A priority patent/EP0987942A4/en
Publication of WO1998038854A1 publication Critical patent/WO1998038854A1/en
Publication of WO1998038854B1 publication Critical patent/WO1998038854B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention is related to a topical composition which may be applied to skin for the purpose of killing fungus and/or bacteria or for the purpose of promoting hair growth.
  • fungicidal compositions are known in the art. But commonly their effectiveness in addressing fungal and/or bacterial infections in humans is quite limited. It appears in most instances that the human body's own immune system actually defends the infected area of the body, thereby reducing the amount of the antibacterial and/or fungicidal substances which pass through the barrier of the immune system and reach the infection. By reducing the free transfer of the disease from the affected area to the healthy areas, the body prevents or reduces the spread of the disease. But this function has the drawback of impeding the transfer of antibiotics and fungicides to affected areas where they may perform their function of killing the infection.
  • the present inventor has found that by suppressing the immune system, a freer transfer of antibiotics and/or fungicides can be achieved; the more the immune system is suppressed, the more effective the antibiotics and/or fungicides become.
  • compositions which are asserted to promote hair growth in humans.
  • qrowth compositions seem to work by stimulating blood flow -afhd require ⁇ constant application, suggesting that whatever hair growth results is forced.
  • these compositions increase blood flow providing more nourishment for hair growth than occurred before the application of the compositions.
  • such compositions offer only limited success and only with a limited class of users.
  • an object of the present invention is to provide a composition which may be applied to human skin where it will successfully kill bacterial and/or fungal infections, without causing adverse side effects.
  • a further object of the present invention is to provide a composition which may be applied to human skin, particularly the head, where it will promote the growth of hair.
  • the present invention is a composition intended for the topical application to human skin, comprising
  • an antibiotic medication such as penicillin VK (Rugby) , doxycycline (Rugby) or erythrocin (Abbott Laboratories) ;
  • an antihistamine such as bromohenivamine (Schein) , Chlorpromazine (Schein) , diphenylhydramine hydrochloride (Parke- Davis) , chlorpheniramine malate, chlorpromazine malate, and bromopheniramine.
  • Certain embodiments of the invention may also contain (3) an antiinflammatory medication such as aspirin (Goldline) , hydrocortisone cream (Rugby) , hydrocortisone powder (Parma-Tek Inc.) and hydrocortisone acetate injectable (Merck Sharp & Dohme) , and/or (4) a bactericide combination of neomycin / bactracine / polymyxin B sulfate.
  • the inventor has surprisingly found that this combination of ingredients produces remarkable effects in treating fungal and/or bacterial infections in humans and in promoting human hair growth .
  • the human body's immune system builds a multifunctional defensive barrier between an affected area and an unaffected area of the body.
  • the ability to provide medication to the affected area is also reduced in direct relation to the effectiveness of this interference.
  • composition described herein has been found to be effective in the treatment of conditions, such as dandruff, staph sores, fungal infections, urethra infection, scarring, and prostate infection.
  • Relative amounts of 50 to 80% by weight antihistamine to 50 to 20% by weight antibiotic/fungicide appear to be effective.
  • Preferred relative amounts being 55 to 80% by weight antihistamine to 45 to 20% by weight antibiotic/fungicide, more preferred relative amounts being 60 to 75% by weight antihistamine to 40 to 25% by weight antibiotic/fungicide, and most preferred relative amounts being 65 to 75% by weight antihistamine to 35 to 25% by weight antibiotic/fungicide.
  • antibiotics and fungicides which are known to work well with the particular infection to be treated, should be tried first.
  • the paste mixture is allowed to be dry on the skin, the addition of a cream may be helpful in holding the mixture together in place on the skin surface.
  • Topical compositions according to the present invention which contain cortisone cream, virtually eliminate infections within a few hours to a few days. Also, pain and bruising is reduced with the use of cortisone cream.
  • the components of the present invention may also be combined with blephamide as a carrier.
  • Embodiments of the invention containing a sulfa drug as the antibiotic result in particularly fast recovery, as well as offering good anaesthetic effects. Especially good anaesthetic results are obtained when the sulfa drug is contained in Blephamide.
  • the present invention may also be characterized as a method for reducing pain through the application of the presently disclosed pharmaceutical composition when the antibiotic is a sulfa drug.
  • Blephamide appears to be particularly effective in treating conditions on the eye lid or conditions effecting the surface of the skin such as burns.
  • the healing process with the topical composition of the present invention appears to be different from that with conventional compositions. While the healing period with the present invention may be 50 to 75% longer than with such conventional compositions, the pain, swelling, and discoloration associated with the infected area are greatly reduced. Scarring is also reduced and may actually be eliminated. Nerve regrowth is speeded up. Further, there is little or no scab growth because the body no longer regards the infected area as a location which must be protected.
  • the wound should be covered completely by the composition of the present invention throughout the first half of the healing process. Also, a portion of the area peripheral to the wound should be covered. For the remaining healing time, the wound itself should remain covered. If pain returns, full coverage should be restored.
  • the effective use of the present invention can be accelerated if the applied inventive composition is kept covered and moist.
  • Penicillin has been a widely prescribed antibiotic composition since the 1930's.
  • Diphenylhydra ine is marketed in the United States under the name BENADRYLTM.
  • Hydrocortisone is marketed in the United States under the name HYDROSKINTM.
  • the bactericide combination of neomycin / bactracine / polymyxin B sulfate is marketed in the United States under the name BACTINETM.
  • hair growth compositions seem to work by stimulating blood flow and require constant application. This suggests that whatever hair growth results is forced growth. In other words, an increased blood flow provides more nourishment for hair growth than occurred before the application of these compositions. Further, such compositions offer only limited success and only with a limited class of users. But with the composition of the present invention, one or more applications will grow hair in about eight weeks. Further, since no maintenance applications are required, the present inventor infers that the hair growth is not forced hair growth. Since the hair growth continues, even without further applications, for six months or more, the present inventor believes that the cause of such growth is an increase in nutrients which results in greater hair growth, rather than greater blood flow. The present inventor concludes that some forms of hair loss may be caused by infection (s) in the area of the hair follicle. The composition of the present invention reduces or kills such infection (s) .
  • the infection (s) seem to return after a period of six months or more. Accordingly, new applications of the inventive composition are needed to maintain the hair.
  • composition of the present invention also has the effect of reducing or treating dandruff.
  • dandruff can be virtually eliminated as hair growth renews.
  • 10 grains of antibiotic and 10 grains of antihistamine are mixed together. To that mixture is added 6 to 12, or even more, grains of cream or ointment. If that cream or ointment is not cortisone cream, 3 or 4 grains of cortisone cream may be included. A liquid may be required at this point to achieve the proper consistency.
  • Injectable antihistamine and antiinflammatory preparations may be used.
  • the addition of water or mineral oil to noninjectable antihistamine and antiinflammatory preparations is also effective in making paste of a workable consistency.
  • the powder from twelve 500 mg. penicillin tablets was combined with two 50 mg. ampules of injectable BenadrylTM. Added thereto was about a 2-1/2" to 3" squirt of Rugby HydroskinTM and a few drops of BactineTM until the mixture was thinner than honey.
  • This composition was then rubbed into a clean scalp at night and removed each morning for eight days. Within eight weeks hair growth was observed.
  • Example I A patient suffered a fungus infection under his toenails which had ridged them up to a considerable extent. On a clean toenail three applications of the composition of Example I brought back the pink skin under the nail. All of the white was gone.
  • Example I To a patient suffering from scar tissue behind his ear was subjected to repeated applications of the composition of Example I. Over an extended period of about three months, all of the scar tissue but one wrinkle and all of the effected flesh but one dot were gone.

Abstract

Disclosed is a pharmaceutical composition intended for the topical application to human skin, comprising (A) as an effective ingredient, a mixture comprising (1) an antibiotic medication, (2) an antihistamine; and (B) a physiologically acceptable carrier. Also disclosed is a method for treatment using this composition.

Description

PHARMACEUTICAL COMPOSITION AND METHODS FOR USING IT
Background of the Invention
This is a Continuation-in-Part of Application No. 08/812,410 filed March 6, 1997.
The present invention is related to a topical composition which may be applied to skin for the purpose of killing fungus and/or bacteria or for the purpose of promoting hair growth.
Many fungicidal compositions are known in the art. But commonly their effectiveness in addressing fungal and/or bacterial infections in humans is quite limited. It appears in most instances that the human body's own immune system actually defends the infected area of the body, thereby reducing the amount of the antibacterial and/or fungicidal substances which pass through the barrier of the immune system and reach the infection. By reducing the free transfer of the disease from the affected area to the healthy areas, the body prevents or reduces the spread of the disease. But this function has the drawback of impeding the transfer of antibiotics and fungicides to affected areas where they may perform their function of killing the infection.
The present inventor has found that by suppressing the immune system, a freer transfer of antibiotics and/or fungicides can be achieved; the more the immune system is suppressed, the more effective the antibiotics and/or fungicides become.
Also, a number of compositions are known which are asserted to promote hair growth in humans. However, such hair, qrowth compositions seem to work by stimulating blood flow -afhd require^ constant application, suggesting that whatever hair growth results is forced. In other words, these compositions increase blood flow providing more nourishment for hair growth than occurred before the application of the compositions. Further, such compositions offer only limited success and only with a limited class of users.
Accordingly, an object of the present invention is to provide a composition which may be applied to human skin where it will successfully kill bacterial and/or fungal infections, without causing adverse side effects.
A further object of the present invention is to provide a composition which may be applied to human skin, particularly the head, where it will promote the growth of hair.
These and other objects are achieved by the present invention.
Summary of the Invention
The present invention is a composition intended for the topical application to human skin, comprising
(1) an antibiotic medication such as penicillin VK (Rugby) , doxycycline (Rugby) or erythrocin (Abbott Laboratories) ; and
(2) an antihistamine such as bromohenivamine (Schein) , Chlorpromazine (Schein) , diphenylhydramine hydrochloride (Parke- Davis) , chlorpheniramine malate, chlorpromazine malate, and bromopheniramine. Certain embodiments of the invention may also contain (3) an antiinflammatory medication such as aspirin (Goldline) , hydrocortisone cream (Rugby) , hydrocortisone powder (Parma-Tek Inc.) and hydrocortisone acetate injectable (Merck Sharp & Dohme) , and/or (4) a bactericide combination of neomycin / bactracine / polymyxin B sulfate.
The inventor has surprisingly found that this combination of ingredients produces remarkable effects in treating fungal and/or bacterial infections in humans and in promoting human hair growth .
Detailed Description of the Invention
The human body's immune system builds a multifunctional defensive barrier between an affected area and an unaffected area of the body. The more dangerous the immune system considers this affected area to be, the more pronounced the interference between the affected and unaffected areas becomes. The ability to provide medication to the affected area is also reduced in direct relation to the effectiveness of this interference.
The present applicant has found that by temporarily reducing the effectiveness of this defensive area, ordinary medications become very effective very quickly. The composition described herein is intended to accomplish this result.
The composition described herein has been found to be effective in the treatment of conditions, such as dandruff, staph sores, fungal infections, urethra infection, scarring, and prostate infection. Relative amounts of 50 to 80% by weight antihistamine to 50 to 20% by weight antibiotic/fungicide appear to be effective. Preferred relative amounts being 55 to 80% by weight antihistamine to 45 to 20% by weight antibiotic/fungicide, more preferred relative amounts being 60 to 75% by weight antihistamine to 40 to 25% by weight antibiotic/fungicide, and most preferred relative amounts being 65 to 75% by weight antihistamine to 35 to 25% by weight antibiotic/fungicide.
Although many combinations of types and brands of antihistamines and antibiotics and/or fungicides may be used effectively, antibiotics and fungicides which are known to work well with the particular infection to be treated, should be tried first.
It is desirable to mix the ingredients into a paste because a liquid is needed to carry the mixture of the invention into the affected area. The paste mixture should be kept moist to continue its effectiveness and to prevent undue drying of the mixture. If the paste mixture becomes unduly dry after application to the skin surface, it will tend to fall off the skin.
If the paste mixture is allowed to be dry on the skin, the addition of a cream may be helpful in holding the mixture together in place on the skin surface.
The best results appear to be obtained with hydrocortisone cream. The antiinflammatory characteristics of the cortisone are believed to aid in the free flow of the antibiotics. Topical compositions according to the present invention, which contain cortisone cream, virtually eliminate infections within a few hours to a few days. Also, pain and bruising is reduced with the use of cortisone cream.
The components of the present invention may also be combined with blephamide as a carrier. Embodiments of the invention containing a sulfa drug as the antibiotic result in particularly fast recovery, as well as offering good anaesthetic effects. Especially good anaesthetic results are obtained when the sulfa drug is contained in Blephamide. In fact the present invention may also be characterized as a method for reducing pain through the application of the presently disclosed pharmaceutical composition when the antibiotic is a sulfa drug. Blephamide appears to be particularly effective in treating conditions on the eye lid or conditions effecting the surface of the skin such as burns.
The healing process with the topical composition of the present invention appears to be different from that with conventional compositions. While the healing period with the present invention may be 50 to 75% longer than with such conventional compositions, the pain, swelling, and discoloration associated with the infected area are greatly reduced. Scarring is also reduced and may actually be eliminated. Nerve regrowth is speeded up. Further, there is little or no scab growth because the body no longer regards the infected area as a location which must be protected.
The wound should be covered completely by the composition of the present invention throughout the first half of the healing process. Also, a portion of the area peripheral to the wound should be covered. For the remaining healing time, the wound itself should remain covered. If pain returns, full coverage should be restored.
Existing scars may be softened and reduced by application of the inventive composition.
The effective use of the present invention can be accelerated if the applied inventive composition is kept covered and moist.
The application of heat to the wound is also helpful.
Penicillin has been a widely prescribed antibiotic composition since the 1930's.
Diphenylhydra ine is marketed in the United States under the name BENADRYL™.
Hydrocortisone is marketed in the United States under the name HYDROSKIN™.
The bactericide combination of neomycin / bactracine / polymyxin B sulfate is marketed in the United States under the name BACTINE™.
Turning to the use of the present invention for hair growth, the present inventor has concluded that hair growth compositions seem to work by stimulating blood flow and require constant application. This suggests that whatever hair growth results is forced growth. In other words, an increased blood flow provides more nourishment for hair growth than occurred before the application of these compositions. Further, such compositions offer only limited success and only with a limited class of users. But with the composition of the present invention, one or more applications will grow hair in about eight weeks. Further, since no maintenance applications are required, the present inventor infers that the hair growth is not forced hair growth. Since the hair growth continues, even without further applications, for six months or more, the present inventor believes that the cause of such growth is an increase in nutrients which results in greater hair growth, rather than greater blood flow. The present inventor concludes that some forms of hair loss may be caused by infection (s) in the area of the hair follicle. The composition of the present invention reduces or kills such infection (s) .
On the other hand, the infection (s) seem to return after a period of six months or more. Accordingly, new applications of the inventive composition are needed to maintain the hair.
The composition of the present invention also has the effect of reducing or treating dandruff. By varying the composition of the present invention, dandruff can be virtually eliminated as hair growth renews.
In some embodiments of the present invention, 10 grains of antibiotic and 10 grains of antihistamine are mixed together. To that mixture is added 6 to 12, or even more, grains of cream or ointment. If that cream or ointment is not cortisone cream, 3 or 4 grains of cortisone cream may be included. A liquid may be required at this point to achieve the proper consistency.
Injectable antihistamine and antiinflammatory preparations may be used. The addition of water or mineral oil to noninjectable antihistamine and antiinflammatory preparations is also effective in making paste of a workable consistency.
The present invention is further described by the following examples which should not be construed as limiting the scope of the invention in any respect.
Example I
The powder from twelve 500 mg. penicillin tablets was combined with two 50 mg. ampules of injectable Benadryl™. Added thereto was about a 2-1/2" to 3" squirt of Rugby Hydroskin™ and a few drops of Bactine™ until the mixture was thinner than honey.
This composition was then rubbed into a clean scalp at night and removed each morning for eight days. Within eight weeks hair growth was observed.
Example II
A patient suffered a fungus infection under his toenails which had ridged them up to a considerable extent. On a clean toenail three applications of the composition of Example I brought back the pink skin under the nail. All of the white was gone.
Example III
To a patient suffering from scar tissue behind his ear was subjected to repeated applications of the composition of Example I. Over an extended period of about three months, all of the scar tissue but one wrinkle and all of the effected flesh but one dot were gone.

Claims

What I Claim Is:
1. A pharmaceutical composition intended for the topical application to human skin, comprising
(A) as an effective ingredient, a mixture comprising
(1) an antibiotic medication;
(2) an antihistamine; and
(B) a physiologically acceptable carrier.
2. A method for treating a fungus infection in a human suffering from the fungus infection, comprising the step of applying the pharmaceutical composition of claim 1 to the skin of the human.
3. A method for promoting hair growth in a human, comprising the step of applying the pharmaceutical composition of claim 1 to the skin of the human, wherein the antibiotic is kaphlex.
4. The pharmaceutical composition of claim 1, wherein the antiinflammatory medication is hydrocortisone cream.
5. The pharmaceutical composition of claim 1, wherein the mixture further comprises an antiinflammatory medication.
6. The pharmaceutical composition of claim 1, wherein the mixture further comprises a bactericide combination of neomycin / bactracine / polymyxin B sulfate.
7. The pharmaceutical composition of claim 1, wherein the antihistamine is bromopheniramine.
8. The pharmaceutical composition of claim 1, wherein the antihistamine is chlorpromazine.
9. The pharmaceutical composition of claim 1, wherein the antihistamine is diphenylhydramine hydrochloride.
PCT/US1998/003922 1997-03-06 1998-03-04 Pharmaceutical composition and methods for using it WO1998038854A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP53861698A JP2001514625A (en) 1997-03-06 1998-03-04 Medicinal compounds and their use
EP98908784A EP0987942A4 (en) 1997-03-06 1998-03-04 Pharmaceutical composition and methods for using it

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/812,410 US5753247A (en) 1995-03-20 1997-03-06 Method of treating fungal infections
US08/812,410 1997-03-06
US09/031,067 1998-02-26
US09/031,067 US5932236A (en) 1997-03-06 1998-02-26 Pharmaceutical composition and methods for using it

Publications (2)

Publication Number Publication Date
WO1998038854A1 true WO1998038854A1 (en) 1998-09-11
WO1998038854B1 WO1998038854B1 (en) 1998-10-22

Family

ID=26706787

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/003922 WO1998038854A1 (en) 1997-03-06 1998-03-04 Pharmaceutical composition and methods for using it

Country Status (4)

Country Link
US (3) US5932236A (en)
EP (1) EP0987942A4 (en)
JP (1) JP2001514625A (en)
WO (1) WO1998038854A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312474B1 (en) 1999-09-15 2001-11-06 Bio-Vascular, Inc. Resorbable implant materials
US20030049283A1 (en) * 2001-08-31 2003-03-13 Vandell Victor E. Scalp desensitizing formulation
US20030198616A1 (en) * 2002-04-23 2003-10-23 Combe Incorporated Moisturizing skin gel and method
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
CN102614298B (en) * 2012-04-26 2013-10-30 肖连元 Scalding spray and preparation method thereof
CN109999177A (en) * 2019-04-04 2019-07-12 中南大学 Application of the polymyxin in preparation treatment neural cell injury drug

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3764672A (en) * 1964-08-05 1973-10-09 Upjohn Co Composition and process of treatment using lincomycin derivatives
US4226850A (en) * 1976-11-12 1980-10-07 Packman Elias W Methods for controlling perspiration
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US5648397A (en) * 1995-03-20 1997-07-15 Bass; James S. Pharmaceutical composition and methods for using it

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289757A (en) * 1978-02-28 1981-09-15 The Upjohn Company Method for treating inflammation
WO1996020712A1 (en) * 1994-12-30 1996-07-11 American Home Products Corporation Clear non-alcoholic hydrocortisone solutions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3764672A (en) * 1964-08-05 1973-10-09 Upjohn Co Composition and process of treatment using lincomycin derivatives
US4226850A (en) * 1976-11-12 1980-10-07 Packman Elias W Methods for controlling perspiration
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US5648397A (en) * 1995-03-20 1997-07-15 Bass; James S. Pharmaceutical composition and methods for using it

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0987942A4 *

Also Published As

Publication number Publication date
JP2001514625A (en) 2001-09-11
US5993841A (en) 1999-11-30
EP0987942A1 (en) 2000-03-29
US5932236A (en) 1999-08-03
EP0987942A4 (en) 2004-04-21
US6066676A (en) 2000-05-23

Similar Documents

Publication Publication Date Title
US5980875A (en) Honey preparations
EP0789584B1 (en) Application of superoxide dismutase in liposomes
EP1863469B1 (en) A topical analgesic composition
US6171604B1 (en) Honey preparations
US3777016A (en) Composition and method for the treat-ment of damaged skin
HUP0102899A2 (en) Process for preparation of compositions for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
US20070110739A1 (en) Wipe away pain
SK287249B6 (en) Medicinal products with cicatrizing action comprising biguanide derivatives
US5536502A (en) Skin-tear medicament and method of use
EP1050300A2 (en) Selective antibacterial composition
US5932236A (en) Pharmaceutical composition and methods for using it
US20110189160A1 (en) Veterinary Topical Agent
US5648397A (en) Pharmaceutical composition and methods for using it
US5734080A (en) Reaction product of arginine and p-aminobenzoic acid, cosmetic, and human and animal health compositions thereof
US7198794B1 (en) Topical formulation for treating fingernails and toenails
RU2202362C2 (en) Composition for topical usage containing human epidermis factor growth
JP3899267B2 (en) Use of tosylchloramide to treat skin, mucous membrane, organ or tissue disorders
US6844014B1 (en) Herbal healing lotion for veterinary use
JP2000212090A (en) Skin-modifying agent
US20020045600A1 (en) Topical skin treatment for sea lice, insect bites and skin irritation
US3017325A (en) Therapeutic composition for topical application and method of applying the same
US6294205B1 (en) Botanical composition for soothing skin
RU2282450C2 (en) Method for treating purulent wounds in animals
RU2124355C1 (en) Method of an agent devising for wound treatment
RU2030868C1 (en) Composition for struggle against sarcoptoidosis in animals and demodecosis in dogs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 538616

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998908784

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998908784

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998908784

Country of ref document: EP